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Furthermore, small diameter melanomas represent a 
distinct clinicopathological entity that do not have to have 
enough clinical, dermoscopical and histopathological cri-
teria to differentiate from atypical nevi. Reported fre-
quency of small diameter melanomas is 11.4–38.2%6. Only 
a few case reports of in situ melanomas with a diameter 
of less than 2 mm were reported6–8. The smallest reported 
melanoma with dermoscopic features which evoked suspi-
cion to malignancy had a diameter of 1.6 mm7,9.
Morever, superfi cial atypical melanocytic proliferations 
of uncertain signifi cance (SAMPUS) is confi ned to the 
epidermis and papillary dermis, without evidence of tu-
morigenic proliferation or mitotic activity. These lesions 
are clinically, dermoscopically and pathologically chal-
lenging as differential diagnosis of melanoma in situ is 
diffi cult or impossible to rule out (Figure 1)10.
Moreover, featureless melanoma are melanoma with-
out clinical and dermoscopic characteristics of melanoma 
but digital dermoscopy monitoring and total body photog-
raphy are used to identify it only based on the criteria of 
the change over time11,12.
The incidence of melanoma of the skin is rising more 
rapidly than any other cancer1. Due to the fact that mela-
noma is an aggressive skin tumor with high mortality 
rate, the main goal of clinical and dermoscopic examina-
tion is the early detection of melanoma, in fact, the recog-
nition of thin melanoma, especially melanoma in situ, 
which is at the present time still very challenging. Early 
recognition and excision of melanoma is the most impor-
tant factor for improving patient survival2. In contrast, 
melanoma in the advanced stages is usually recognizable 
by the naked eye, and is not curable as invasion thickness 
increases3.
Melanoma in situ is the earliest stage of melanoma. 
About 75% of melanomas develop de novo and only 25% 
are associated with a nevus4. Clinically, de novo melano-
mas are small brown to black macula with an irregular 
outline, whose diameter varies from 2mm to several cen-
timeters, and the period of this lateral growth may last 
for years. Often the patient recognizes that the lesion is 
growing and digitate extensions can be noticed during the 
period of radial growth, when the melanoma cells are con-
fi ned to the epidermis5.
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A B S T R A C T
The lack of effective therapies for patients with advanced melanoma establishes an early recognition as the aim of 
clinical and dermoscopic examination, which is the most important factor for improving patient survival and decreases 
the treatment and management costs. Melanoma in situ is the earliest stage of melanoma. The features of early melanomas, 
especially in those lesions smaller than 3mm, can be very subtle clinically, dermoscopically and pathohistologically, and 
it is often impossible to discriminate between a melanoma and nevus. Clinically, de novo melanomas are small brown to 
black macula with an irregular outline. In melanomas developing in a nevus, there is an asymmetry of the lesion with 
marked change in color and/or shape of the pre-existing nevus. Dermoscopically, early stages of melanoma show the same 
global features as thicker melanomas, but in a more subtle way. Asymmetry is the most important parameter; multiple 
colors are rare. Signifi cant local melanoma-specifi c criteria, especially when present at the periphery, are irregular pig-
ment network, irregular streaks, and irregular dots/globules, while blue-white structures are rarely found.
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Over the last two decades sensitive diagnostic tech-
niques have been developing in order to improve detection 
of both early and featureless melanomas12.
Dermoscopy is a noninvasive technique that allows in 
vivo observation by magnifi cation and illumination of the 
skin structures, from the epidermis to the papillary der-
mis, that are not seen with the naked eye13. Dermoscopy 
is a diagnostic tool in clinical examination of pigmented 
and non-pigmented skin lesions that improves melanoma 
detection and decreases unnecessary excision rate of be-
nign lesions and this have been proved in numerous stud-
ies, including three meta-analyses2,14–18.
Early Melanoma, Melanoma in situ, thin 
Invasive Lesions ≤1 mm, Featureless Melanoma, 
small Diameter Melanoma and Melanoma 
Developing in Nevus
Early melanoma includes melanoma in situ and thin 
invasive melanomas less than or equal to 1 mm in 
depth13–19. The latter have 85–90% chance of a 10 year-
survival after surgical excision with a 1 cm margin13.
In general, dermoscopic characteristics for melanoma 
are asymetry in two axes, atypical dots/globules, atypical 
network, streaks, pseudopods, blotches, blue-white veil, 
structureless area, atypical vessels, milky red area, der-
moscopic island, peppering, white like scar area4,20–21.
However, the features of early melanomas, especially 
in those lesions smaller than 3mm, can be very subtle 
clinically, dermoscopically and pathohistologically, and it 
is often impossible to discriminate between a melanoma 
and nevus.
Thin melanomas dermoscopically show asymmetry in 
two axes, three or more colors, atypical dots and globules 
and atypical network or streaks13. Melanoma in situ main-
ly tends to have 2 colors, blue-whitish veil, grey-blue areas, 
black dots and irregular extensions and branched streaks. 
Less frequently there are brown globules, irregular pig-
mented network, pseudopods, and depigmentation19. Thin 
invasive melanomas are associated with white scar-like 
area and linear and/or dotted vessels19. Therefore, dermo-
scopic criteria for melanoma in situ and invansive mela-
noma are similar19.
According to Silva VPM et al. atypical network is more 
frequently found in thin invasive melanoma than in mela-
noma in situ13. The regression interferes with the asses-
ment of the level of invasion in melanoma and carries 
great histopathologic controversy, as well as can be a con-
founding feature for histopathologic differentiation be-
tween melanoma and nevus22. According to Seidenari S et 
al. regression variables are blue areas (structureless, re-
ticular and globular), peppering, white areas, blue-whitish 
veil, pink areas, light brown areas and regression of der-
moscopic structures. Regression and the number of regres-
sion parameter are more frequent and extensive in inva-
sive melanomas than in melanoma in situ22.
Dissapearance of the network or of the dermoscopic 
structures in circumscribed regions of the lesion form the 
areas of light brown pigmentation withouht structures22. 
Therefore, melanoma in situ have mainly light brown ar-
eas (Figure 2) and regression of dermoscopic structures 
and less blue areas and pink areas, otherwise character-
istic for invasive melanoma. Among blue areas the reticu-
lar type is characteristic for melanoma in situ, although 
structureless type can also be present22. Light brown 
structureless areas are statistically signifi cant discrimi-
nator and one of the most reliable predictors for thin mel-
anomas23. Dermoscopic islands have been associated with 
thin melanomas arising from a nevus but in previously 
described study islands were less frequent4. Also, the same 
study showed that regression is not the only characteristic 
and that is not more frequent for invasive melanomas, but 
that is also present in in-situ melanomas as light brown 
structureless pigmentation, while in invasive melanomas 
it presents as white scare-like area and peppering. Inva-
sive melanomas also tend to have multiple colors (three or 
more) and atypical network or streaks, especially appear-
ing at the periphery. Since there is no defi nitive diferenti-
ating criteria between the atypical nevus and melanoma 
in situ in many clinical cases, other different morphologic 
features have been described in order to determine more 
Fig. 1. Dermoscopic image: combination of globular, reticular and 
nonspecifi c global structure, asymmetry of the structure with ir-
regular globules at periphery, atypical network and blotch cen-
trally; inserted clinical images of a brown pigmeted lesion of 4mm 
on the upper back of the 44-year-old man with negative family 
history for melanoma and syndroma nevi dysplastici, and with-
out history of change of nevi; clinical examination reveald more 
than 50 nevi with mainly reticular global structure; patohistology 
diagnosis is Superfi cial atypical melanocytic proliferations of 
uncertain signifi cance.
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specifi c potential descriptor. One of them is so-called »mis-
tletoe sign«, which appears in the infl ammatory stage of 
the melanocytic nevus and in melanoma in situ, and is an 
indication for the excision of suspicious lesions. It implies 
multiple, well circumscribed areas, consisting of non uni-
form, at times pseudo-dichotomously brunched structures, 
resembling pseudopods, which are not reticular, arising 
from an overall reticular and homogenous pattern24.
Pizzichetta MA et al. also showed that asymmetric 
pigmentation, multicomponent pattern in the combination 
with irregular distribution, and peripheral location of 
negative pigmented network are helpful as additional fea-
tures in distinguishing melanoma lesions from other con-
trol lesions25. They reported high specifi city 77.4%, but low 
sensitivity 34.6% of negative pigmented network for the 
diagnosis of melanoma25.
When morphology of early or featureless melanoma is 
unrecognizable, Lallas et al. suggested that clinicians 
should use seven management rules, which might help in 
improving early and correct diagnosis of melanomas that 
do not meet the standard morphologic features. Following 
these seven specifi c simple and practical rules should in-
tegrate clinical and dermoscopical examination: 1) look 
basically at all lesions, 2) undress high risk patients, 3) 
use the 10 seconds rule in single lesion, 4) compare and 
monitor multiple moles, 5) excise doubtful nodular lesions, 
6) combine clinical and dermoscopic criteria, 7) combine 
clinical and histopathological criteria26.
Small Diameter Melanoma
Dermoscopically, small diameter melanoma present 
with atipycal pigmented network or irregular globules and 
streaks, multiple colors, blue-white veil or regression and 
De Giorgi et al. expressed that these features should aro-
use suspicion of melanoma even in small lesions27.
Melanoma Developing in a Nevus
In melanomas developing from a nevus, there is an 
evident marked change in color and/or shape of pre-exist-
ing nevus, leading to an asymmetric appearance of the 
entire lesion11.
Sequential Dermoscopy Imaging
Recognition of early and featureless melanoma can be 
improved by follow up with digital dermoscopy, revealing 
morphologic changes by sequentional monitoring thus of-
fering better management of pigmented lesions in every-
day practice. Dermoscopic follow up of melanocytic lesions 
allows observation of dermoscopic alterations over time, 
and thus, detection of melanomas in early stages, while 
reducing the excision rate, which especially refers to mul-
tiple nevi patients. With digital follow up melanomas that 
at baseline lacked dermoscopic features can be recog-
nized1,28,29. According to Kittler et al. with longer folllow-
up, melanomas tend to enlarge asymetrically with archi-
tectural and color change, and nevi tended to enlarge 
symetrically without architectural and color change11. 
When follow-up was shorter than 4.5 months the observed 
changes or dermoscopy features of melanomas and chang-
ing nevi could not have been differentiated11.
The decision for surgical intervention should be made 
after follow up with digital dermoscopy28,30.
When using digital dermoscopy follow up, the propor-
tion of thin melanomas and in situ melanomas is higher 
than expected in general population30. Assessment of in-
dividual lesions is followed up in short term interval, while 
medium/long term follow up refers to patients with mul-
tiple nevi with or without personal and/or familial history 
of melanoma, as well patients with atypical mole syn-
drome28. Since there is an increasing trend of thin mela-
nomas in the population, high risk patients should be fol-
lowed up regularly through follow up programs in specifi ed 
centers and institutions, which allow early recognition 
and good prognosis, even when both clinical and dermo-
scopic features of melanoma are lacking. Follow up in-
cludes comparison of clinical images e.g. total body pho-
tography as well in order to detect newly developed lesions, 
that could be de novo melanoma and therefore an early 
melanoma.
Fig. 2. Dermoscopic image: light brown pigmentation and asy-
metrically pigmented follicular oppenings; inserted clinical image 
of newly developed otherwise asymptomatic lesion on the anterior 
part of the lower leg of a 40-year-old woman with few nevi on the 
body with mainly reticular global structure; patohistology diag-
nosis is Melanoma in situ.
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Limitations of Dermoscopy
Although dermoscopy helps to achieve diagnostic ac-
curacy for melanoma, since dermoscopic criteria of mela-
noma appear earlier than the clinical characteristics, 
histopathological examination is indispensable and is still 
considered as a gold diagnostic standard, having decisive 
contribution to the defi nitive diagnosis of melanoma. Since 
featureless and early melanomas may present with un-
characteristic dermoscopic appearance, and may lack 
some specifi c dermoscopic features, because morphologic 
features of melanoma have not yet been fully developed, 
as well as they can be clinically and dermoscopically in-
distinguishable from benign lesions, dermoscopy is found 
to be limited, and melanoma may be overlooked30. These 
cases of melanoma that are diffi cult to diagnose are re-
ported with the prevalence of 5–10%14. Despite available 
algorithms and methods for classifying the lesions some-
times it is very diffi cult to distinguish among them, and 
even experienced clinicians have diganostic accuracy be-
low 85%, especially when differentiating early melanomas 
from melanocytic nevi30. It is also shown that 3-color test, 
another in a series of algorithms, reevaluated by Blum et 
al., is not sensitive enough to detect early melanoma, due 
to the fact that only one or two colors may be present in 
early melanoma, depending on the thickness of the le-
sion14.
Conclusion
Melanoma is still a major public health problem world-
wide. It can be prevented by early recognition of the earli-
est stages of melanoma. Dermoscopy is a part of clinical 
examination of nevi and in general of pigmented and non-
pigmented skin lesions as a complete skin examination, 
and sequential dermoscopy imaging can detect an early 
melanoma.
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DERMATOSKOPIJA I RANI MELANOM
S A Ž E T A K
Obzirom na nedostatak učinkovite terapije za uznapredovali melanomom, rano prepoznavanje melanoma je osnovni 
cilj kliničkog i dermoskopskog pregleda, jer je to najvažniji čimbenik za unapređenje preživljavanja pacijenata s mela-
nomom. Melanom in situ je najranija faza melanoma. Značajke ranog melanoma, posebno u promjenama manjima od 3 
mm, mogu biti vrlo suptilne klinički, dermoskopski i patohistološki, a često je nemoguće izdiferencirati melanom od 
nevusa. Klinički, de novo melanomi su male smeđe do crne makule s nepravilnim rubovima. U melanomima koji se 
razvijaju iz nevusa postoji asimetrija promjene sa značajnom promjenom u boji i/ili obliku već postojećeg nevusa. Der-
moskopski, rane faze melanoma pokazuju iste, ali diskretnije globalne/osnovne karkateristike kao deblji/uznapredovali 
melanomi. Asimetrija je najvažniji parametar; više boja je rijetkost. Značajni lokalno-specifi čni kriteriji melanoma, 
posebno kada su prisutni na periferiji, su nepravilna pigmentna mreža, nepravilni pigmentni izdanci i nepravilne 
točkaste strukture, a plavo-bijele strukture se rijetko nalaze.
